- cafead Jan 11, 2022 at 11:52: AM
via Strategic collaboration with Pfizer leverages Dren Bio’s proprietary platform to develop bispecific antibodies that connect tumor cells with myeloid cells resulting in immune stimulation, targeted phagocytosis and the cross-presentation of tumor neoantigens to potentially promote durable clinical responses –
– Dren Bio received $25 million upfront payment as part of overall deal for selected oncology targets that includes over $1 billion in potential cash payments plus potential future product-based sales royalties –
article source
– Dren Bio received $25 million upfront payment as part of overall deal for selected oncology targets that includes over $1 billion in potential cash payments plus potential future product-based sales royalties –
article source